AR020803A1 - Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento - Google Patents

Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento

Info

Publication number
AR020803A1
AR020803A1 ARP990105185A ARP990105185A AR020803A1 AR 020803 A1 AR020803 A1 AR 020803A1 AR P990105185 A ARP990105185 A AR P990105185A AR P990105185 A ARP990105185 A AR P990105185A AR 020803 A1 AR020803 A1 AR 020803A1
Authority
AR
Argentina
Prior art keywords
same
pharmaceutically acceptable
acceptable salt
fexofenadine
composition
Prior art date
Application number
ARP990105185A
Other languages
English (en)
Original Assignee
West Gregory Donald
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by West Gregory Donald filed Critical West Gregory Donald
Publication of AR020803A1 publication Critical patent/AR020803A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composicion que comprende (i) fexofenadina o una sal farmacéuticamente aceptable de la misma y (ii) un excipiente farmacéutico que aumenta lasolubilidad de la fexofenadina o su sal en agua. El excipiente farmacéutico es preferiblemente unaciclod extrina. El uso de dicha composicionpara la manufactura de un medicamento para la administracion de fexofenadina o una sal farmacéuticamente aceptable de la misma para la nariz o los ojos,para el tratamiento de la rinitis y para controlar laliberaci on de fexofenadina o una sal farmacéuticamente aceptable de la misma cuando es administradaa la nariz o a los ojos.
ARP990105185A 1998-10-13 1999-10-13 Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento AR020803A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9822170.8A GB9822170D0 (en) 1998-10-13 1998-10-13 Novel formulations of fexofenadine

Publications (1)

Publication Number Publication Date
AR020803A1 true AR020803A1 (es) 2002-05-29

Family

ID=10840370

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990105185A AR020803A1 (es) 1998-10-13 1999-10-13 Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento

Country Status (11)

Country Link
US (1) US20010051613A1 (es)
EP (1) EP1121123A2 (es)
JP (1) JP2003519083A (es)
AR (1) AR020803A1 (es)
AU (1) AU757786B2 (es)
CA (1) CA2346307A1 (es)
GB (1) GB9822170D0 (es)
NO (1) NO20011886L (es)
NZ (1) NZ510887A (es)
WO (1) WO2000021510A2 (es)
ZA (1) ZA200102918B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US6613906B1 (en) 2000-06-06 2003-09-02 Geneva Pharmaceuticals, Inc. Crystal modification
US7138133B2 (en) 2001-10-10 2006-11-21 The Procter & Gamble Company Orally administered liquid compositions
BR0306329A (pt) * 2002-05-29 2005-04-26 Aventis Pharmaceuticals Holdin Método de tratamento de asma
AR039703A1 (es) * 2002-06-20 2005-03-09 Novartis Consumer Health Sa Composiciones nasales
JP4569080B2 (ja) * 2002-07-17 2010-10-27 大正製薬株式会社 点鼻剤組成物
WO2005030331A1 (en) * 2003-09-26 2005-04-07 Fairfield Clinical Trials, Llc Combination antihistamine medication
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
US20070110788A1 (en) * 2005-11-14 2007-05-17 Hissong James B Injectable formulation capable of forming a drug-releasing device
DOP2006000274A (es) 2005-12-14 2007-10-15 Sanofi Aventis Us Llc Formulación de suspensión de fexofenadina
US20070264296A1 (en) 2006-05-10 2007-11-15 Myntti Matthew F Biofilm extracellular polysachharide solvating system
US7976873B2 (en) 2006-05-10 2011-07-12 Medtronic Xomed, Inc. Extracellular polysaccharide solvating system for treatment of bacterial ear conditions
US7993675B2 (en) 2006-05-10 2011-08-09 Medtronic Xomed, Inc. Solvating system and sealant for medical use in the sinuses and nasal passages
US7959943B2 (en) 2006-05-10 2011-06-14 Medtronics Xomed, Inc. Solvating system and sealant for medical use in the middle or inner ear
US8088095B2 (en) 2007-02-08 2012-01-03 Medtronic Xomed, Inc. Polymeric sealant for medical use
US20090062242A1 (en) * 2007-08-28 2009-03-05 Agi Therapeutics Plc Methods and compositions for treating gastrointestinal conditions
ES2759373T3 (es) 2008-06-12 2020-05-08 Medtronic Xomed Inc Producto para el tratamiento de heridas crónicas con un sistema extracelular de solvatación de sustancias poliméricas
EP2346324A4 (en) 2008-10-06 2012-10-10 Microbial Defense Systems Llc ANTIMICROBIAL COMPOSITION AND METHODS OF MAKING AND USING
US20120101159A1 (en) * 2009-04-27 2012-04-26 Laboratorio De Aplicaciones Farmacodinamicas, S.A. Ibuprofen lysinate oral suspension
CZ302789B6 (cs) 2009-11-25 2011-11-09 Zentiva, K. S. Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
EP3456200B1 (en) 2011-05-10 2023-05-03 Next Science IP Holdings Pty Ltd Article having an antimicrobial solid and use thereof
AR094761A1 (es) 2013-02-14 2015-08-26 Sanofi Sa Composición farmacéutica para administración oral que comprende fexofenadina y proceso para preparar la misma
AU2015301054B2 (en) 2014-08-08 2020-05-14 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
TWI778069B (zh) 2017-06-02 2022-09-21 日商特一華製藥股份有限公司 難水溶性成分經可溶化之微膠粒及含有該微膠粒之液劑
EP3707202A1 (en) 2017-11-08 2020-09-16 Materias S.r.l. In situ gelifying powder

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
EP0085367A1 (en) * 1982-01-26 1983-08-10 Air Products And Chemicals, Inc. Amination of hydrogen sulfate esters of hydroxyalkyl tertiary amines
IT1183574B (it) * 1985-05-08 1987-10-22 Eurand Spa Metodo per ottenere una sospensione estemporanea omogenea di microcapsule
AR245888A1 (es) * 1989-01-23 1994-03-30 Merrell Pharma Inc Procedimiento para la preparacion de una composicion farmaceutica liquida de derivados de piperidinoalcanol.
WO1991016929A1 (en) * 1990-05-10 1991-11-14 Novo Nordisk A/S A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols
IT1246188B (it) * 1990-07-27 1994-11-16 Resa Farma Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.
IT1263831B (it) * 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
EP0709099A3 (en) * 1994-09-28 1996-07-24 Senju Pharma Co Aqueous suspension for nasal administration containing cyclodextrin
US5574045A (en) * 1995-06-06 1996-11-12 Hoechst Marion Roussel, Inc. Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
US20020111495A1 (en) * 1997-04-04 2002-08-15 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
US6027746A (en) * 1997-04-23 2000-02-22 Warner-Lambert Company Chewable soft gelatin-encapsulated pharmaceutical adsorbates
CN1253508A (zh) * 1997-04-30 2000-05-17 沃尼尔－朗伯公司 局部鼻用抗炎组合物
PT1003528E (pt) * 1997-08-14 2003-02-28 Aventis Pharma Inc Metodo para aumentar a biodisponibilidade da fexofenadina e seus derivados
US6451815B1 (en) * 1997-08-14 2002-09-17 Aventis Pharmaceuticals Inc. Method of enhancing bioavailability of fexofenadine and its derivatives
US6103735A (en) * 1998-10-09 2000-08-15 Schering Corporation Composition and method for treating allergic diseases
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions

Also Published As

Publication number Publication date
ZA200102918B (en) 2003-07-09
EP1121123A2 (en) 2001-08-08
CA2346307A1 (en) 2000-04-20
NZ510887A (en) 2004-12-24
WO2000021510A2 (en) 2000-04-20
AU6219599A (en) 2000-05-01
NO20011886D0 (no) 2001-04-11
GB9822170D0 (en) 1998-12-02
AU757786B2 (en) 2003-03-06
JP2003519083A (ja) 2003-06-17
WO2000021510A3 (en) 2000-07-20
NO20011886L (no) 2001-04-11
US20010051613A1 (en) 2001-12-13

Similar Documents

Publication Publication Date Title
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
ES2170069T3 (es) 1-alfa-hidroxiprevitamina d para administracion oral.
ES2188782T3 (es) Formulaciones farmaceuticas que contienen darifenacina.
AR005281A1 (es) Composicion farceutica oral , procedimientos para su manufactura y uso de esa composicion farmaceutica para la preparacion de medicamentos. .
CR6458A (es) Composiciones de valdecoxib
AR037255A1 (es) Composiciones farmaceuticas que contienen oxibutinina
DE3778781D1 (de) Antiphlogistika enthaltende pharmazeutische formulierungen mit gesteuerter freigabe.
ATE165000T1 (de) Dosierungsform zur verzoegerten wirkstofffreisetzung
CU23468B7 (es) Forma de dosificación de pramipexol en una dosis única diaria
MX9203444A (es) Medicamentos.
ATE67407T1 (de) Pharmazeutische zubereitung mit abgabeeigenschaften.
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
AR004391A1 (es) Formulacion de liberacion controlada para farmacos basicos escasamente solubles.
ES2530719T3 (es) Formulaciones de oxicodona para ser administradas una vez al día
ES2082288T3 (es) Composiciones terapeuticas para administracion intranasal de ketorolaco.
CO4970819A1 (es) Tratamiento de disfuncion sexual femenina en una hembra humana
ES2147294T3 (es) Compuestos terapeuticos.
AR039164A1 (es) Sales de venlafaxina de baja solubilidad en agua
AR040709A1 (es) Formulacion de lamotrigina de liberacion prolongada y uso de la misma para su preparacion
BR9709838A (pt) Regime de administração que fornece um perfil de plasma no sangue de um inibidor de h+,k+-atpase composição farmacêutica oral uso da mesma e de inibidor h+,k+-atpase e processos para melhorar a inibição de secreção de ácido gástrico e o efeito terapêutico no tratamento de perturbações gastrintestinais e para receber um perfil estendido de plasma de um inibidor de h+,k+-atpase
BR9916860A (pt) Método de reduzir colesterol do sangue e/outriglicerìdios do sangue em um indivìduo mamìfero,preparação em forma de unidade de dosagem, e,conjunto para administrar oralmente a mesma
AR019053A1 (es) Uso de 2'2'-difluoronucleosidos para la preparacion de un medicamento y composicion farmaceutica y producto farmaceutico que los contienen
ES2135342B1 (es) Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.
AR036312A1 (es) Composicion farmaceutica
NO962752L (no) Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose